As an SGLT2 inhibitor, the dosage and administration of Inpefa should be adjusted according to individual patient conditions. Special attention should be paid to the use of Inpefa during pregnancy and monitoring of renal function in special populations.

Standard usage and dosage

1. Regular dose for adults: once a day, one tablet each time (including 200mg of Soragliflozin), recommended to be taken in the morning to match the circadian rhythm.

2. Medication method: Swallow the whole tablet, it can be taken with food or alone, but avoid taking it with high-fat meals to affect absorption rate.

Medication for special populations

(1) Pregnant women: prohibited. Animal experiments have shown a risk of fetal developmental abnormalities, and medication discovered during pregnancy should be terminated immediately.

(2) Breastfeeding women: Medications may be secreted through breast milk, and medication should be stopped or breastfeeding should be suspended during breastfeeding.

(3) Children: Insufficient safety data for patients under 18 years old, not recommended for use.

(4) Elderly individuals: No need to adjust the starting dose, but need to strengthen renal function monitoring (eGFR testing every 3 months).

(5) Renal dysfunction: When eGFR<45mL/min/1.73m ², it should be reduced to 100mg/day; Disabled when<30mL/min/1.73m ².

(6) Liver function impairment: mild to moderate without dose adjustment; Child Pugh Class C patients are contraindicated.

Principle of dose adjustment

When blood sugar control is poor: it is not recommended to increase the dosage on your own, and dietary and exercise compliance should be evaluated first.

2. Hypoglycemia management: When used in combination with insulin, it may be necessary to reduce insulin dosage by 20-30%.

3. Pre - and post-operative management: Medication should be suspended for 3 days before the scheduled surgery, and renal function should be restored after the surgery is stable.

Standard storage conditions

1. Temperature requirement: It should be stored at room temperature of 20 ° C to 25 ° C, with short-term fluctuations allowed within the range of 15 ° C to 30 ° C, to avoid extreme temperature affecting the chemical stability of the drug.

2. Packaging management: The tablets should be kept in their original aluminum-plastic blister packaging until taken to prevent moisture or physical damage. It is recommended to use them within 6 months after opening.